The 5th LNP Formulation & Process Development Summit has successfully concluded in Boston, bringing together leading innovators across the global RNA delivery ecosystem. As a CDMO focused on integrated mRNA-LNP solutions, Enorna participated extensively through exhibition showcases, poster presentations, and a featured technical presentation—engaging directly with global leaders advancing the frontier of LNP technologies and therapeutics.

On March 6–7, the "2026 In Vivo CAR‑T Deep Dive Workshop," co‑hosted by Enorna, TONACEA, and other organizations, was successfully held in Shanghai. The workshop focused on the industrialization of in vivo CAR‑T, bringing together academic experts, industry pioneers, and investors from both viral and non‑viral delivery fields. Participants engaged in practical and in‑depth discussions on core topics including R&D innovation, CMC challenges, IND applications, and clinical translatio

January 15, 2026 — Epigenic Therapeutics (Shanghai) Co., Ltd. ("Epigenic"), a clinical-stage biotech company focused on innovative drug discovery and development, announced that its novel epigenetic regulation therapy, EPI‑003, has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B (CHB).

To help researchers more conveniently access validated mRNA and mRNA-tLNP, Enorna officially launches its first batch of ready-to-use mRNA & tLNP off-the-shelf products, providing customers with standardized, high-quality solutions.

EPI-003, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B (CHB).